Table 2.
MTS-associated periocular sebaceous neoplasms: survey responders
| Ophthalmic pathologists, n (%) | Ocular oncologists, n (%) | Oculoplastic surgeons, n (%) | |
|---|---|---|---|
| Practice location | |||
| USA | 28/56 (50) 28/56 (50) | 8/31 (26) | 13/16 (81) |
| Europe | 11/56 (20) | 3/31 (10) | 0/16 (0) |
| Canada | 2/56 (3.5) | 2/31 (6) | 1/16 (6) |
| Asia | 6/56 (11) | 8/31 (26) | 0/16 (0) |
| Australia | 3/56 (5) | 3/31 (10) | 1/16 (6) |
| Central/South America | 4/56 (7) | 5/31 (16) | 1/16 (6) |
| Other | 2/56 (3.5) | 2/31 (6) | 0/16 (0) |
| Practice type Eye pathology/ Ophthalmology hospital | 39/56 (70) | 20/31 (65) | 1/16 (6) |
| General pathology/ Oncology/plastics hospital | 10/56 (18) | 5/31 (16) | 3/16 (19) |
| Private practice | 2/56 (3) | 4/31 (13) | 12/16 (75) |
| Other | 5/56 (9) | 2/31 (6) | 0/16 (0) |
| Are MTS screening guidelines for patients with periocular sebaceous neoplasia clear? | |||
| Extremely clear | 6/55 (11) | 4/31 (13) | 2/16 (12) |
| Somewhat clear | 23/55 (42) | 8/31 (26) | 6/16 (38) |
| Not so clear | 18/55 (33) | 16/31 (51) | 6/16 (38) |
| Not at all clear | 8/55 (14) | 3/31 (10) | 2/16 (12) |
MTS, Muir-Torre Syndrome.